# Safety, Pharmacokinetics, and Pharmacodynamics of MK-6325 in Hepatitis C Virus (HCV) Infections (MK-6325-003)

> **NCT01329913** · PHASE1 · COMPLETED · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 36 (actual)

## Conditions studied

- Hepatitis C

## Interventions

- **DRUG:** MK-6325
- **DRUG:** Placebo to MK-6325
- **DRUG:** MK-6325
- **DRUG:** Placebo to MK-6325
- **DRUG:** MK-6325
- **DRUG:** Placebo to MK-6325

## Key facts

- **NCT ID:** NCT01329913
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-05
- **Primary completion:** 2012-04
- **Final completion:** 2012-04
- **Target enrollment:** 36 (ACTUAL)
- **Last updated:** 2015-02-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01329913

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01329913, "Safety, Pharmacokinetics, and Pharmacodynamics of MK-6325 in Hepatitis C Virus (HCV) Infections (MK-6325-003)". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT01329913. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*